Kiniksa Pharmaceuticals International, plc (KNSA)
Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
63. 95
+2.84
+4.6474%
$
4.66B Market Cap
84.4 P/E Ratio
- Div Yield
712,400 Volume
-0.16 Eps
$ 61.11
Previous Close 
Want to track KNSA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased demand following the recent sales force expansion. The improved outlook for Arcalyst warrants an increase in the valuation range.
Seekingalpha | 1 year ago
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09.
Zacks | 1 year ago
